Abstract Number: 1847 • ACR Convergence 2025
Spatial transcriptomics reveals a complex microanatomic patterning of complement mediated inflammation and fibrosis in Class III pediatric lupus nephritis associated with local histologic injury
Background/Purpose: Lupus nephritis (LN) occurs in over 50% of patients with pediatric systemic lupus erythematosus (pSLE) and results in significant morbidity due to suboptimal kidney…Abstract Number: 2453 • ACR Convergence 2025
Belimumab Is Associated with Lower Risk of Progression to LN Compared with Standard of Care in Patients with SLE
Background/Purpose: LN develops in ~40% of patients with SLE and is associated with increased risk of morbidity, including end-stage kidney disease, and mortality. Belimumab, a…Abstract Number: 0601 • ACR Convergence 2025
Precipitants and Long-Term Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort Study and Systematic Review
Background/Purpose: Posterior reversible encephalopathy syndrome (PRES) is an underrecognized neuroradiologic complication of SLE, characterized by acute neurological symptoms and vasogenic edema on neuroimaging. Its precipitating…Abstract Number: 0661 • ACR Convergence 2025
Real-world Effectiveness and Usage of Voclosporin: Data from the Enlight-LN Registry
Background/Purpose: The 2024 American College of Rheumatology Lupus Nephritis (LN) Guideline recommends triple immunosuppressive therapy, including the option of a calcineurin inhibitor (CNI)-based regimen, for…Abstract Number: 1273 • ACR Convergence 2025
Effectiveness of IV Cyclophosphamide and Mycophenolate Mofetil in the Treatment of Pediatric Systemic Lupus Erythematosus with Lupus Nephritis
Background/Purpose: Lupus nephritis (LN) is more common in children (occurs in 50-82%) compared to adults. Cyclophosphamide (CYC) and mycophenolate mofetil (MMF) are both treatment options…Abstract Number: 1530 • ACR Convergence 2025
The Renal Activity Index for Lupus Identifies and Predicts Complete Renal Remission or Absence of Kidney Involvement in Systemic Lupus Erythematosus
Background/Purpose: Effective, non-invasive disease activity and treatment response assessments are needed for patients with systemic lupus erythematosus (SLE), especially if associated with kidney disease, i.e.…Abstract Number: 1851 • ACR Convergence 2025
Endotype Discovery in Systemic Lupus Erythematosus Using Multi-Omic Approaches: Toward Precision Insights into Cardiovascular and Renal Damage
Background/Purpose: Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder characterized by marked clinical variability, which complicates both diagnosis and treatment. Among its most severe…Abstract Number: 2458 • ACR Convergence 2025
Obecabtagene autoleucel (obe-cel), a CD19-targeting Autologous Chimeric Antigen Receptor T-cell Therapy (CAR T) with a fast off-rate binding domain, in Patients (pts) with Severe, Refractory Systemic Lupus Erythematosus (srSLE): Preliminary Results from the Phase I CARLYSLE Study
Background/Purpose: Pts with srSLE have limited remaining treatment options and represent a population with an unmet need. CD19 CAR Ts have potential for deep depletion…Abstract Number: 0610 • ACR Convergence 2025
The Role of Active Nephritis, Compared to Active Non-Renal SLE, in Pregnancy Outcomes
Background/Purpose: The ACR recommends against pregnancy in patients with SLE with high disease activity. These recommendations do not distinguish between the various manifestations of active…Abstract Number: 0663 • ACR Convergence 2025
iPSC-Derived Off-the-Shelf anti-CD19 CAR T cells Deliver Improved Clinical Outcomes in Lupus with Reduced or No Conditioning Chemotherapy
Background/Purpose: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy shows promise in autoimmune disease. However, autologous CAR T-cell therapy is limited by prolonged pre- and…Abstract Number: 1282 • ACR Convergence 2025
Real-world use of belimumab in childhood-onset SLE in Spain: cross-sectional analysis from a multicenter study (JULES registry)
Background/Purpose: SLE is a multisystemic autoimmune disease with several manifestations. Childhood-onset SLE (cSLE) has a more severe disease course than adult-onset SLE, with a higher…Abstract Number: 1540 • ACR Convergence 2025
Association of Hypoalbuminemia with Serious Infections in Systemic Lupus Erythematosus Patients Receiving Dialysis
Background/Purpose: Lupus nephritis, a key manifestation of systemic lupus erythematosus (SLE), can progress to end-stage kidney disease and increase patient burden. While patients with SLE…Abstract Number: 1853 • ACR Convergence 2025
SAP Expression in SLE T Cells is Associated with Differentiation Towards Pro-Inflammatory Effector Subsets.
Background/Purpose: SAP is an adaptor protein that mediates signaling downstream of SLAMF T cell receptors. SAP deficiency results in X-linked Lymphoproliferative immunodeficiency characterized by impaired…Abstract Number: 2462 • ACR Convergence 2025
Precision Dosing is Needed to Establish Predictable Exposure to the Active Metabolite of Mycophenolate Mofetil (MMF) in Pediatric Lupus Nephritis (LN)
Background/Purpose: The safety and effectiveness of MMF for the treatment of LN have been tested in adult and pediatric patients. MMF, a prodrug, is rapidly…Abstract Number: 0611 • ACR Convergence 2025
Venous Thromboembolism in Patients with Lupus Nephritis: Frequency and Risk Factors – A Cohort Study
Background/Purpose: Venous thromboembolism (VTE) is a known complication of systemic lupus erythematosus (SLE), yet there is a lack of high-quality studies specifically focused on lupus…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 44
- Next Page »